A Phase 1, Open-label, Parallel-group Study to Evaluate Sotagliflozin Safety and Pharmacokinetics in Subjects With Varying Degrees of Renal Function
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Lexicon Pharmaceuticals
- 21 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
- 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2016 Planned End Date changed from 1 Oct 2016 to NULL.